Drug Czar Warns Cannabis 'Still Illegal' Despite Schedule III Move

The White House Office of National Drug Control Policy director Sara Carter Bailey delivered a stark reminder to cannabis markets this week, emphasizing that marijuana remains federally illegal despite its reclassification to Schedule III. Her comments on Newsmax underscore the complex regulatory reality facing cannabis companies as they navigate the gap between rescheduling expectations and actual legal reform.

Bailey's clarification that Schedule III status only permits medical research and doctor-supervised use highlights the limited scope of the Trump administration's rescheduling decision. This narrow interpretation creates immediate challenges for state-licensed cannabis operators who hoped rescheduling would provide broader federal protection for their businesses. The drug czar's emphasis on continued illegality signals the administration may take a restrictive approach to implementing the new classification.

The regulatory uncertainty carries direct financial implications for cannabis companies already struggling with banking restrictions and tax burdens under Section 280E. While Schedule III reclassification theoretically allows tax deductions for business expenses, Bailey's comments suggest federal enforcement agencies may maintain their current stance toward state-legal cannabis operations. This disconnect between rescheduling and practical legalization leaves operators in the same compliance limbo that has constrained industry growth.

Cannabis companies face particular pressure as investors recalibrate expectations around federal reform timelines. The drug czar's statements effectively separate medical cannabis research from the broader commercial market, potentially limiting which businesses can claim federal compliance under the new schedule. This distinction becomes critical as companies evaluate expansion plans and capital allocation strategies in an environment where federal policy remains hostile to recreational cannabis.

The administration's narrow interpretation of Schedule III also impacts state-level policy development, as governors and legislators watch federal signals before advancing their own cannabis programs. Bailey's comments suggest the White House views rescheduling as a medical research tool rather than a stepping stone toward broader legalization, creating headwinds for companies betting on accelerated federal reform under the new administration.